Natpar (Parathyroid Hormone)

Parathyroid hormone binds to PTH1 receptors on bone‑forming cells and renal tubules, activating intracellular signaling that increases osteoblastic activity, reduces bone resorption, and enhances renal calcium reabsorption while promoting phosphate excretion. These actions collectively raise serum calcium levels and improve bone mineralization.

The dosage of Natpar is individualized; a qualified prescriber determines the amount, frequency, and duration based on the patient’s serum calcium levels, weight, and clinical response. Dosing instructions are provided on the prescription label and should be followed exactly as directed by the treating physician.

Safety data for Natpar during pregnancy and lactation are limited. It should only be used if the potential therapeutic benefit justifies any possible risk to the fetus or infant, and the decision must be made by the prescribing clinician in consultation with the patient.

To request Natpar, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling—and necessary import documentation.

The primary alternative to Natpar is conventional therapy with oral calcium and active vitamin D analogues. Unlike those, Natpar directly replaces deficient parathyroid hormone, offering more precise control of serum calcium and potentially reducing the need for high oral supplement doses. Choice of therapy depends on individual patient factors and physician assessment.

Natpar must be stored refrigerated at 2‑8 °C (36‑46 °F). It should be kept in its original packaging, protected from light, and must not be frozen or shaken. If the product reaches room temperature, it should be returned to refrigeration promptly and used within the time frame specified by the manufacturer.

Natpar is given by subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a healthcare professional or a trained patient following aseptic technique. The injection site should be rotated to minimize local irritation, and the dose is administered according to the prescriber’s instructions.

The most serious risks include severe hypercalcemia, which can cause cardiac arrhythmias, renal impairment, or neurological symptoms, and rare hypersensitivity reactions such as anaphylaxis. Long‑term therapy may carry a theoretical risk of osteosarcoma, although this is extremely uncommon. Patients should be monitored closely for these events.

Natpar is contraindicated in individuals with known hypersensitivity to parathyroid hormone or any excipients, those with active hypercalcemia, and patients with severe renal impairment unless dose adjustments are made. It should also be used with caution in pregnant or nursing women, and only under specialist supervision.